Leland Gershell
Stock Analyst at Oppenheimer
(4.60)
# 220
Out of 5,124 analysts
150
Total ratings
52.11%
Success rate
35.28%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $87.11 | +224.88% | 1 | Dec 23, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Outperform | $35 | $13.13 | +166.67% | 1 | Dec 23, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $28.86 | +87.11% | 6 | Dec 8, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $12.52 | +91.69% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $9.03 | +265.45% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $7.85 | +129.30% | 5 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $31.12 | +15.68% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $46.55 | +86.90% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $20.86 | +283.51% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $46.30 | +137.58% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $76.49 | -20.25% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $397.65 | +23.22% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $9.93 | +101.41% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $107.04 | +2.77% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $213.24 | +5.05% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $23.41 | +32.42% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.00 | +150.00% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $840.95 | -15.81% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.35 | +198.51% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $59.43 | +64.90% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $41.21 | +26.18% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $188.97 | -22.21% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.14 | +2,236.45% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $25.42 | +108.50% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.74 | +220.86% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $3.60 | +138,788.89% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.33 | +369.04% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $6.59 | +203.49% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $23.34 | +24.25% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $18.16 | +92.73% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.31 | +3,174.39% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.77 | +2,498.08% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.02 | +543.56% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.00 | +2,900.00% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.87 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $31.21 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.85 | +5,782.35% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $13.96 | - | 5 | Mar 31, 2020 |
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $87.11
Upside: +224.88%
Aardvark Therapeutics
Dec 23, 2025
Initiates: Outperform
Price Target: $35
Current: $13.13
Upside: +166.67%
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $28.86
Upside: +87.11%
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $12.52
Upside: +91.69%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $9.03
Upside: +265.45%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $7.85
Upside: +129.30%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $31.12
Upside: +15.68%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $46.55
Upside: +86.90%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $20.86
Upside: +283.51%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $46.30
Upside: +137.58%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $76.49
Upside: -20.25%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $397.65
Upside: +23.22%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $9.93
Upside: +101.41%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $107.04
Upside: +2.77%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $213.24
Upside: +5.05%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $23.41
Upside: +32.42%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $4.00
Upside: +150.00%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $840.95
Upside: -15.81%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $3.35
Upside: +198.51%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $59.43
Upside: +64.90%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $41.21
Upside: +26.18%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $188.97
Upside: -22.21%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.14
Upside: +2,236.45%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $25.42
Upside: +108.50%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.74
Upside: +220.86%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $3.60
Upside: +138,788.89%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.33
Upside: +369.04%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $6.59
Upside: +203.49%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $23.34
Upside: +24.25%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $18.16
Upside: +92.73%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.31
Upside: +3,174.39%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.77
Upside: +2,498.08%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.02
Upside: +543.56%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.00
Upside: +2,900.00%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.87
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $31.21
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $0.85
Upside: +5,782.35%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $13.96
Upside: -